Dapagliflozin (Monograph)
Brand name: Farxiga
Drug class: Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Chemical name: (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-d-glucitol,
Molecular formula: C21H25ClO6
CAS number: 461432-26-8
Introduction
Antidiabetic agent; sodium-glucose cotransporter 2 (SGLT2) inhibitor.1 53 55
Uses for Dapagliflozin
Type 2 Diabetes Mellitus
Glycemic Control
Used as monotherapy as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.1 2 3 15 32 34
Used in combination with other antidiabetic agents (e.g., metformin and/or a sulfonylurea, a peroxisome proliferator-activated receptorγ [PPARγ] agonist [thiazolidinedione], a dipeptidyl peptidase-4 [DPP-4] inhibitor), a glucagon-like peptide 1 [GLP-1] receptor agonist, and/or insulin) as an adjunct to diet and exercise in patients with type 2 diabetes mellitus who have not achieved adequate glycemic control with dapagliflozin monotherapy.1 4 5 6 7 8 9 10 12 13 16 52
Used in fixed combination with extended-release metformin hydrochloride (Xigduo XR) as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus when treatment with both drugs is appropriate.53
Used in fixed combination with saxagliptin (Qtern) or with saxagliptin and extended-release metformin hydrochloride (Qternmet XR) as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.55 101 Manufacturer states that the fixed combination of dapagliflozin, saxagliptin, and extended-release metformin (Qternmet XR) is intended for use only in patients currently receiving metformin.101
Current guidelines for the treatment of type 2 diabetes mellitus generally recommend metformin as first-line therapy in addition to lifestyle modifications in patients with recent-onset type 2 diabetes mellitus or mild hyperglycemia because of its well-established safety and efficacy (i.e., beneficial effects on glycosylated hemoglobin [hemoglobin A1c; HbA1c], weight, and cardiovascular mortality).698 704 705
In patients with metformin contraindications or intolerance (e.g., risk of lactic acidosis, GI intolerance) or in selected other patients, some experts suggest that initial therapy with a drug from another class of antidiabetic agents (e.g., a GLP-1 receptor agonist, SGLT2 inhibitor, DPP-4 inhibitor, sulfonylurea, thiazolidinedione, basal insulin) may be acceptable based on patient factors.698
May need to initiate therapy with 2 agents (e.g., metformin plus another drug) in patients with high initial HbA1c (>7.5% or ≥1.5% above target).698 704 In such patients with metformin intolerance, some experts suggest initiation of therapy with 2 drugs from other drug classes with complementary mechanisms of action. 698
Consider early initiation of combination therapy for the treatment of type 2 diabetes mellitus to extend the time to treatment failure and more rapidly attain glycemic goals.704
For patients with inadequate glycemic control on metformin monotherapy, consider patient comorbidities (e.g., atherosclerotic cardiovascular disease [ASCVD], established kidney disease, heart failure), hypoglycemia risk, impact on weight, cost, risk of adverse effects, and patient preferences when selecting additional antidiabetic agents for combination therapy.698 704 705 706
Consider early introduction of insulin for severe hyperglycemia (e.g., blood glucose of ≥300 mg/dL or HbA1c >9–10%), especially if accompanied by catabolic manifestations (e.g., weight loss, hypertriglyceridemia, ketosis) or symptoms of hyperglycemia.698 704
Experts recommend that patients with type 2 diabetes mellitus who have established (or are at a high risk for) ASCVD, established kidney disease, or heart failure receive a GLP-1 receptor agonist or SGLT2 inhibitor with demonstrated cardiovascular disease benefit.704 705 In patients with these comorbidities, consider GLP-1 receptor agonist or SGLT2 inhibitor therapy independently of patient's HbA1c.704
In patients with type 2 diabetes mellitus and CKD, consider a GLP-1 receptor agonist or SGLT2 inhibitor shown to reduce the risk of CKD progression, cardiovascular events, or both, in addition to metformin therapy or in those in whom metformin cannot be used.704 705 706
In patients on metformin monotherapy without established ASCVD or indicators of high ASCVD risk, heart failure, or CKD, base decision regarding addition of other antidiabetic agents on avoidance of adverse effects, cost, and individual patient factors.704
Not indicated for treatment of type 1 diabetes mellitus or diabetic ketoacidosis.1 53 55
Reduction in Heart Failure-Related Hospitalization
Used to reduce the risk of hospitalization for heart failure in patients with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors.1 70 698 699 704 705
Beneficial Effects on Renal Function
Some experts suggest that SGLT2 inhibitor therapy be considered to reduce risk of CKD progression, cardiovascular events, or both in patients with type 2 diabetes mellitus and diabetic kidney disease with albuminuria† [off-label] (eGFR ≥30 mL/minute per 1.73 m2 and urinary albumin >30 mg/g [particularly >300 mg/g] creatinine).706
Reduction in Cardiovascular Death and Heart Failure-Related Hospitalization
Used to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure and reduced ejection fraction (NYHA class II–IV).1 90
Beneficial effects of dapagliflozin demonstrated in patients with chronic heart failure with or without coexisting type 2 diabetes mellitus.1 90
Related/similar drugs
lisinopril, metoprolol, furosemide, metformin, carvedilol, spironolactone, triamcinolone
Dapagliflozin Dosage and Administration
General
-
Correct volume depletion prior to initiating dapagliflozin; assess renal function prior to treatment and periodically thereafter.1 50 53 101
Administration
Oral Administration
Dapagliflozin: Administer once daily in the morning, with or without food.1
Fixed combination of dapagliflozin and extended-release metformin or dapagliflozin, saxagliptin, and extended-release metformin: Administer once daily in the morning with food to reduce the adverse GI effects of the metformin component.53 101
Fixed combination of dapagliflozin and saxagliptin: Administer once daily in the morning, with or without food.55
Fixed-combination tablets of dapagliflozin and extended-release metformin; dapagliflozin and saxagliptin; or dapagliflozin, extended-release metformin, and saxagliptin: Swallow whole; do not crush, cut, or chew.53 55 101
If a dose of dapagliflozin, the fixed combination of dapagliflozin and extended-release metformin, or the fixed combination of dapagliflozin and saxagliptin is missed, take missed dose as soon as it is remembered followed by resumption of regular schedule.1 53 56 If missed dose is not remembered until the time of the next dose, skip missed dose and resume regular schedule.1 53 56 Do not double dose to replace a missed dose.1 53 56
If a dose of the fixed combination containing dapagliflozin, extended-release metformin, and saxagliptin is missed and it is ≥12 hours until the next dose, take the missed dose as soon as remembered.101 If a dose is missed and it is <12 hours until the next dose, skip the missed dose and take the next dose at the usual time.101
Dosage
Dosage of dapagliflozin propanediol is expressed in terms of dapagliflozin.1
Adults
Type 2 Diabetes Mellitus - Glycemic Control
Dapagliflozin
OralInitially, 5 mg once daily.1
If well tolerated, increase dosage to 10 mg once daily in patients who require additional glycemic control.1
Dapagliflozin/Extended-release Metformin Hydrochloride Fixed-combination Therapy
OralInitial dosage based on patient's current regimen with dapagliflozin and/or metformin hydrochloride.53 May gradually increase dosage based on effectiveness and tolerability.53
In patients currently not receiving dapagliflozin, initial recommended dosage of the dapagliflozin component is 5 mg once daily.53 Titrate gradually based on effectiveness and tolerability, up to a maximum dosage of 10 mg of dapagliflozin and 2 g of extended-release metformin hydrochloride daily.53
Patients who are already receiving extended-release metformin hydrochloride in the evening and are switching to the fixed combination of dapagliflozin and extended-release metformin hydrochloride should skip their last dose of metformin hydrochloride before initiating therapy with the fixed combination the following morning.53
Dapagliflozin/Saxagliptin Fixed-combination Therapy
OralRecommended initial dosage in patients not already receiving dapagliflozin therapy is 5 mg of dapagliflozin and 5 mg of saxagliptin once daily in the morning.55
In patients requiring additional glycemic control and tolerating initial dosage, may increase dosage of fixed combination to 10 mg of dapagliflozin and 5 mg of saxagliptin once daily.55
Do not use fixed combination in patients receiving concomitant therapy with a potent CYP3A4/5 inhibitor (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin).55
Dapagliflozin/Extended-release Metformin Hydrochloride/Saxagliptin Fixed-combination Therapy
OralManufacturer states that the fixed-combination preparation containing dapagliflozin, saxagliptin, and extended-release metformin is intended only for patients currently taking metformin.101 Recommended initial dosage based on patient's current antidiabetic drug regimen.101
In patients not already receiving dapagliflozin, recommended initial total daily dosage is dapagliflozin 5 mg, saxagliptin 5 mg, and extended-release metformin hydrochloride 1 or 2 g once daily in the morning.101
Do not use fixed combination in patients receiving concomitant therapy with a potent CYP3A4/5 inhibitor (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin).101
Type 2 Diabetes Mellitus - Reduction in Heart Failure-Related Hospitalization
Dapagliflozin
Oral10 mg once daily.1
Dapagliflozin/Extended-release Metformin Hydrochloride Fixed-combination Therapy
Oral10 mg of dapagliflozin once daily.53
Reduction in Cardiovascular Death and Heart Failure-Related Hospitalization
Dapagliflozin
Oral10 mg once daily.1
Prescribing Limits
Adults
Type 2 Diabetes Mellitus - Glycemic Control
Oral
Dapagliflozin: Maximum of 10 mg daily.1
Fixed combination with extended-release metformin hydrochloride: Maximum of 10 mg of dapagliflozin and 2 g of extended-release metformin hydrochloride daily.53
Fixed combination with saxagliptin: Maximum of 10 mg of dapagliflozin and 5 mg of saxagliptin daily.55
Fixed combination with saxagliptin and extended-release metformin hydrochloride: Maximum of 10 mg of dapagliflozin, 5 mg of saxagliptin, and 2 g of extended-release metformin hydrochloride daily.101
Type 2 Diabetes Mellitus - Reduction in Heart Failure-Related Hospitalization
Oral
Dapagliflozin: Maximum of 10 mg daily.1
Fixed combination with extended-release metformin hydrochloride: Maximum of 10 mg of dapagliflozin and 2 g of extended-release metformin hydrochloride daily.53
Reduction in Cardiovascular Death and Heart Failure-Related Hospitalization
Oral
Dapagliflozin: Maximum of 10 mg daily.1
Special Populations
Hepatic Impairment
Dapagliflozin
Oral
Mild, moderate, or severe hepatic impairment: No dosage adjustment necessary.1
Dapagliflozin/Extended-release Metformin Hydrochloride Fixed-combination Therapy
Oral
Avoid use in patients with hepatic impairment.53
Dapagliflozin/Saxagliptin Fixed-combination Therapy
Oral
Mild, moderate, or severe hepatic impairment: No dosage adjustment necessary.55
Dapagliflozin/Extended-release Metformin Hydrochloride/Saxagliptin Fixed-combination Therapy
Oral
Avoid use in patients with hepatic impairment.101
Renal Impairment
Dapagliflozin
Oral
Glycemic control: No dosage adjustment necessary for eGFR ≥45 mL/minute per 1.73 m2.1 Use not recommended if eGFR 30 to <45 mL/minute per 1.73 m2.1 Contraindicated if eGFR <30 mL/minute per 1.73 m2 and in patients with ESRD or undergoing dialysis.1
Reduction in risk of heart failure-related hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors: No dosage adjustment necessary for eGFR ≥45 mL/minute per 1.73 m2.1 Insufficient data to support dapagliflozin dosage recommendation in patients with eGFR <45 mL/minute per 1.73 m2.1 Contraindicated in patients with ESRD or undergoing dialysis.1
Reduction in risk of cardiovascular death or heart failure-related hospitalization in patients with heart failure and reduced ejection fraction with or without type 2 diabetes mellitus: No dosage adjustment necessary for eGFR ≥30 mL/minute per 1.73 m2.1 Insufficient data to support dapagliflozin dosage recommendation in patients with eGFR <30 mL/minute per 1.73 m2.1 Contraindicated in patients with ESRD or undergoing dialysis.1
Dapagliflozin/Extended-release Metformin Hydrochloride Fixed-combination Therapy
Oral
Mild renal impairment (eGFR ≥45 mL/minute per 1.73 m2): No dosage adjustment necessary.53
Moderate renal impairment: Not recommended if eGFR <45 mL/minute per 1.73 m2.53
Severe renal impairment (eGFR <30 mL/minute per 1.73 m2): Contraindicated.53
Dapagliflozin/Saxagliptin Fixed-combination Therapy
Oral
Mild renal impairment (eGFR ≥45 mL/minute per 1.73 m2): No dosage adjustment necessary.55
Moderate or severe renal impairment: Contraindicated in patients with an eGFR <45 mL/minute per 1.73 m2.55
Geriatric Patients
No dosage adjustment of dapagliflozin necessary based solely on age.1
Sex
Dosage adjustment of dapagliflozin based on patient's sex not necessary.1
Race
Dosage adjustment of dapagliflozin based on race not necessary.1
Body Weight
Dosage adjustment of dapagliflozin based on body weight not necessary.1
Cautions for Dapagliflozin
Contraindications
-
History of serious hypersensitivity reaction to dapagliflozin.1
-
Dapagliflozin is contraindicated in patients with severe renal impairment (eGFR <30 mL/minute per 1.73 m2) when used for glycemic control in patients without established cardiovascular disease or multiple cardiovascular risk factors.1
-
Dapagliflozin is contraindicated in patients with ESRD or undergoing dialysis.1
Warnings/Precautions
Ketoacidosis
Ketoacidosis (e.g., diabetic ketoacidosis, ketoacidosis, ketosis) requiring hospitalization reported with SGLT2 inhibitors; may occur without markedly elevated blood glucose concentrations (e.g., <250 mg/dL).1 39 40 41 42 50
Evaluate for the presence of acidosis, including ketoacidosis, in patients experiencing signs or symptoms of acidosis regardless of the patient's blood glucose concentration; discontinue SGLT2 inhibitor and initiate appropriate treatment to correct acidosis if confirmed.1 39 40 50 (See Advice to Patients.)
Prior to initiating dapagliflozin therapy, consider risk factors that may predispose patients to ketoacidosis (e.g., pancreatic insulin deficiency, reduced caloric intake, alcohol abuse).1 50
Consider discontinuing dapagliflozin for ≥3 days prior to surgery for patients with scheduled surgery.1
Consider temporarily discontinuing SGLT2 inhibitor in patients with other clinical situations known to predispose to ketoacidosis (e.g., prolonged fasting due to acute illness or post-surgery).1 50 Resolve factors for ketoacidosis prior to restarting dapagliflozin.1
Some clinicians suggest monitoring of urine and/or plasma ketone levels if patients feel unwell, regardless of ambient glucose concentrations.40 42
Volume Depletion
May cause intravascular volume contraction.1 Symptomatic hypotension can occur, particularly in patients with impaired renal function (eGFR <60 mL/minute per 1.73 m2), geriatric patients, or patients receiving loop diuretics.1 (See Specific Drugs and Laboratory Tests under Interactions.) Assess and correct intravascular volume status prior to initiating dapagliflozin in such patients.1
Monitor patients for signs and symptoms of hypotension after initiating therapy.1
Renal Effects
Causes intravascular volume contraction and can cause acute kidney injury.1 51
May increase Scr concentration and decrease eGFR; geriatric patients and patients with impaired renal function may be more susceptible to these changes.1 Adverse reactions related to renal function can occur following initiation of the drug.1
Prior to initiating dapagliflozin therapy, consider factors that may predispose patients to acute kidney injury, such as hypovolemia, chronic renal insufficiency, heart failure, and concomitant medications (e.g., diuretics, ACE inhibitors, angiotensin II receptor antagonists, NSAIAs).1 51
Consider temporarily discontinuing dapagliflozin in any setting of reduced oral intake (e.g., acute illness, fasting) or fluid losses (e.g., GI illness, excessive heat exposure).1 51
Evaluate renal function prior to initiation of dapagliflozin and monitor periodically thereafter.1 Discontinue dapagliflozin and initiate appropriate treatment if kidney injury occurs.1 51
Concomitant Therapy with Hypoglycemic Agents
When adding dapagliflozin to therapy with an insulin secretagogue (e.g., a sulfonylurea) or insulin, consider reducing dosage of the concomitant insulin secretagogue or insulin to reduce the risk of hypoglycemia.1 (See Specific Drugs and Laboratory Tests under Interactions.)
Fournier Gangrene
Fournier gangrene (necrotizing fasciitis of the perineum), a rare but serious life-threatening bacterial infection requiring urgent surgical intervention, reported during postmarketing surveillance of men and women with type 2 diabetes mellitus receiving an SGLT2 inhibitor.1 59 60 61 62
Assess patient for necrotizing fasciitis if pain or tenderness, erythema, or swelling in the genital or perineal area occurs in addition to fever or malaise.1 60
If Fournier gangrene suspected, discontinue dapagliflozin and initiate treatment immediately with broad-spectrum antibiotics and, if necessary, perform surgical debridement.1 60 Closely monitor blood glucose concentrations and initiate alternative antidiabetic agent to maintain glycemic control.1 60
Genital Mycotic Infections
Possible increased risk of genital mycotic infections in males (e.g., balanitis) and females (e.g., vulvovaginal mycotic infection).1 11 37 Patients with a history of genital mycotic infections were more likely to develop such infections.1 37
Monitor patients for genital mycotic infections and institute appropriate treatment if these infections occur.1
Urosepsis and Pyelonephritis
May increase the risk of serious urinary tract infections (e.g., urosepsis, pyelonephritis requiring hospitalization).1 50
Prior to initiating dapagliflozin therapy, consider patient factors that may predispose to serious urinary tract infections (e.g., history of difficulty urinating; infection of the bladder, kidneys, or urinary tract).50
Monitor patients for urinary tract infections and initiate treatment if indicated.1 50
Risk of Bone Fracture
Increased risk of bone fracture, along with dose-related decreases in bone mineral density in older adults, observed in patients receiving another SGLT2 inhibitor (canagliflozin).43 Bone fractures observed more frequently than with placebo in patients with moderate renal impairment (eGFR 30 to <60 mL/minute per 1.73 m2) receiving dapagliflozin, usually within 52 weeks of initiating therapy.1 FDA continuing to evaluate bone fracture risk with SGLT2 inhibitors.43
Use of Fixed Combinations
When dapagliflozin is used in fixed combination with metformin, saxagliptin, or other drugs, consider the cautions, precautions, contraindications, and interactions associated with the concomitant agent(s) in addition to those associated with dapagliflozin.1 53 55
Sensitivity Reactions
Hypersensitivity reactions (e.g., angioedema, urticaria, hypersensitivity), some serious, reported.1 53 55 If a hypersensitivity reaction occurs, discontinue dapagliflozin, institute appropriate treatment, and monitor patients until signs and symptoms resolve.1
Specific Populations
Pregnancy
No adequate and well-controlled studies of dapagliflozin in pregnant women.1
Studies in animals indicate that dapagliflozin use during pregnancy may affect renal development and maturation.1
Dapagliflozin therapy not recommended in pregnant women during the second and third trimesters of pregnancy.1
Lactation
Distributed into milk in rats; not known whether distributed into human milk.1 Use of dapagliflozin in women who are breast-feeding not recommended.1
Pediatric Use
Safety and efficacy not established in pediatric patients <18 years of age.1
Geriatric Use
Efficacy similar in patients <65 years of age and those ≥65 years of age after controlling for renal function (eGFR).1 Such patients more likely to experience hypotension.1
Hepatic Impairment
Assess benefits versus risks of dapagliflozin or the fixed combination of dapagliflozin and saxagliptin in patients with severe hepatic impairment; safety and efficacy not established in such patients.1 22 Avoid use of the fixed-combination preparations containing dapagliflozin and extended-release metformin or dapagliflozin, saxagliptin, and extended-release metformin in patients with clinical or laboratory evidence of hepatic impairment.53 101
Renal Impairment
Patients with an eGFR of 45 to <60 mL/minute per 1.73 m2 receiving dapagliflozin had substantial improvement in glycemic control and experienced adverse effects similar to those without renal impairment.1 71 Patients receiving dapagliflozin therapy had a greater reduction in eGFR compared with those receiving placebo; however, renal function generally increased back to baseline values after discontinuing treatment with dapagliflozin.1 71 Patients with renal impairment receiving dapagliflozin for glycemic control may be more likely to experience hypotension and may be at an increased risk for acute kidney injury.1 Patients with an eGFR of 30 to <60 mL/minute per 1.73 m2 receiving dapagliflozin had a greater incidence of bone fractures compared with those receiving placebo.1 35
Impact of hemodialysis on dapagliflozin exposure is not known; contraindicated in patients on dialysis.1
Assess renal function prior to initiation of therapy and periodically thereafter.1
Common Adverse Effects
Dapagliflozin monotherapy: Female genital mycotic infection,1 2 3 4 6 7 8 nasopharyngitis,1 2 3 5 6 7 8 urinary tract infection,1 2 3 4 5 6 8 33 back pain,1 5 8 increased urination,1 male genital mycotic infection,1 2 3 4 7 nausea,1 4 dyslipidemia,1 4 8 constipation,1 discomfort with urination,1 pain in extremity.1 8
Dapagliflozin in combination with extended-release metformin hydrochloride: Female genital mycotic infection,53 nasopharyngitis,53 urinary tract infection,53 diarrhea,53 headache,53 male genital mycotic infection,53 influenza,53 nausea,53 back pain,53 dizziness,53 cough,53 constipation,53 dyslipidemia,53 pharyngitis,53 increased urination,53 discomfort with urination.53
Dapagliflozin in combination with saxagliptin and extended-release metformin hydrochloride: Upper respiratory tract infection,55 urinary tract infection,55 dyslipidemia,55 headache,55 diarrhea,55 back pain,55 genital infection,55 arthralgia.55
Drug Interactions
Metabolism principally mediated by uridine diphosphate-glucuronosyltransferase (UGT) isoenzyme 1A9.1 20
Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes
Did not inhibit CYP-450 isoenzymes 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4 in vitro.1 19 Did not induce CYP isoenzymes 1A2, 2B6, or 3A4 in vitro.1 19
Drugs Affected by Organic Anion Transporter
Dapagliflozin 3-O-glucuronide, inactive metabolite of dapagliflozin, is a substrate of organic anion transport (OAT) 3.1 Dapagliflozin and dapagliflozin 3-O-glucuronide did not meaningfully inhibit OAT1 or OAT3 active transporters; pharmacokinetic interactions unlikely with OAT1 or OAT3 substrates.1
Drugs Affected by Organic Cation Transporter
Did not meaningfully inhibit organic cation transporter (OCT) 2; pharmacokinetic interactions unlikely with substrates of OCT2.1
Drugs Affected by P-glycoprotein Transport
Weak P-glycoprotein substrate; did not meaningfully inhibit P-glycoprotein.1 19 20 Unlikely to affect pharmacokinetics of concurrently administered P-glycoprotein substrates.1
Specific Drugs and Laboratory Tests
Drug or Test |
Interaction |
Comments |
---|---|---|
Antidiabetic agents |
Risk of hypoglycemia increased when used concomitantly with insulin secretagogue (e.g,, sulfonylurea) or insulin1 |
Reduced dosage of insulin or insulin secretagogue may be required to reduce the risk of hypoglycemia1 |
Bumetanide |
Increased bumetanide AUC and peak plasma concentration1 (see also Diuretics entry in this table) |
No dosage adjustment necessary1 |
Digoxin |
No clinically meaningful effect on digoxin AUC or peak plasma concentration1 20 26 |
No adjustment of digoxin dosage necessary1 |
Diuretics |
Possible increased incidence of symptomatic hypotension1 |
Assess and correct intravascular volume prior to dapagliflozin initiation; monitor for signs and symptoms of hypotension after initiating therapy1 |
Glimepiride |
||
Hydrochlorothiazide |
No clinically important effect on pharmacokinetics of either drug1 20 (see also Diuretics entry in this table) |
No dosage adjustment necessary1 |
Mefenamic acid |
Increased dapagliflozin peak plasma concentration and AUC1 20 24 |
No adjustment of dapagliflozin dosage necessary.24 |
Metformin |
No clinically meaningful effect on pharmacokinetics of either drug 1 20 25 |
|
Pioglitazone |
||
Rifampin |
Decreased dapagliflozin peak plasma concentration and AUC 1 20 24 |
|
Simvastatin |
No dosage adjustment necessary1 |
|
Sitagliptin |
No clinically meaningful effect on pharmacokinetics of either drug (single-dose administration)1 |
|
Urine glucose tests (e.g., 1,5-anhydroglucitol assay) |
SGLT2 inhibitors increase urinary glucose excretion and will result in false-positive urine glucose tests; after discontinuation of dapagliflozin 10 mg, elevation in urinary glucose excretion approaches baseline in approximately 3 days1 |
Use alternative methods to monitor glycemic control1 |
Valsartan |
Decreased peak plasma concentrations of valsartan and dapagliflozin and increased valsartan AUC1 20 26 |
No dosage adjustment necessary1 |
Voglibose (not commercially available in the US) |
No clinically meaningful effect on dapagliflozin1 |
|
Warfarin |
No clinically meaningful effect on warfarin pharmacokinetics or pharmacodynamics1 20 26 |
Dapagliflozin Pharmacokinetics
Absorption
Bioavailability
Absolute oral bioavailability: 78%.1 27 Peak plasma concentration usually attained within 2 hours after oral dosing in fasted state.1 18 19 20 23 30
Food
Administration with a high-fat meal decreased peak plasma concentration by up to 50% and prolonged time to peak plasma concentration by approximately 1 hour, but did not alter AUC.1 20 21 These changes are not considered clinically meaningful; administer dapagliflozin with or without food.1 20 21
Special Populations
Mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment: No clinically important differences in peak plasma concentration or AUC.1
Severe hepatic impairment (Child-Pugh class C): AUC and peak plasma concentration increased by 67 and 40%, respectively, compared with individuals with normal hepatic function following a single 10-mg dose of dapagliflozin.1 22
Mild renal impairment: Geometric mean systemic exposure of dapagliflozin at steady state increased by 45% compared with individuals with normal renal function.1
Moderate renal impairment: Geometric mean systemic exposure of dapagliflozin at steady state increased 2.04-fold compared with individuals with normal renal function.1
Severe renal impairment: Geometric mean systemic exposure of dapagliflozin at steady state increased 3.03-fold compared with individuals with normal renal function.1
Distribution
Extent
Extensively distributed.20
Plasma Protein Binding
Special Populations
Renal or hepatic impairment does not meaningfully alter plasma protein binding.1
Elimination
Metabolism
Metabolized principally by UGT1A9 to inactive metabolites.1
Elimination Route
75 and 21% of total radioactivity excreted in urine and feces, respectively, with <21 19 and approximately 15% in urine and feces, respectively, as parent drug.1 20
Half-life
Approximately 12.9 hours following a single oral dose of 10 mg.1
Stability
Storage
Oral
Tablets
Dapagliflozin, the fixed combination of dapagliflozin and extended-release metformin, or the fixed combination of dapagliflozin and saxagliptin: 20–25°C (may be exposed to 15–30°C).1 53 55
Actions
-
Inhibits SGLT2, a transporter expressed in proximal renal tubules and responsible for majority of reabsorption of filtered glucose from the tubular lumen.1 20
-
Reduces reabsorption of filtered glucose and lowers the renal threshold for glucose in a dose-dependent manner, leading to increased urinary glucose excretion.1 17 30 31
-
Increases glucose excretion independent of insulin secretion.36
-
Improves muscle insulin sensitivity;28 29 however, glucosuria induction appears to increase endogenous glucose production.28
-
Endogenous glucose production increases, accompanied by an increase in fasting plasma glucagon concentration.28
Advice to Patients
-
Importance of patient reading medication guide before initiating therapy and each time the drug is dispensed.1 38 53 54 55 56
-
When dapagliflozin is used in fixed combination with other drugs, importance of informing patients of important cautionary information about the concomitant agents.1 53 55
-
Importance of informing patients of the potential risks and benefits of dapagliflozin and of alternative therapies.1 38 Importance of not using dapagliflozin in patients with type 1 diabetes mellitus or diabetic ketoacidosis.1 38
-
Importance of informing patients that ketoacidosis, which can be a life-threatening condition, has been reported with dapagliflozin therapy (sometimes associated with illness or surgery among other risk factors).1 Importance of informing patients and their caregivers of the signs and symptoms of ketoacidosis (e.g., tachypnea or hyperventilation, anorexia, abdominal pain, nausea, vomiting, lethargy, mental status change) and of instructing patients to discontinue dapagliflozin and seek medical advice immediately should they experience any such signs or symptoms.1 39 42 50 Advise patients to use a ketone dipstick to check for ketones in their urine (when possible) if symptoms of ketoacidosis occur, even if blood glucose is not elevated (e.g., <250 mg/dL).1 38 50
-
Importance of informing patients that symptomatic hypotension may occur with dapagliflozin and to report such symptoms to their clinicians.1 38 Inform patients that dapagliflozin-induced dehydration may increase the risk of hypotension and changes in kidney function and that patients should maintain adequate fluid intake.1 38
-
Importance of informing patients that acute kidney injury has been reported with dapagliflozin therapy.1 38 51 Advise patients to seek medical attention immediately if they experience decreased urine output or swelling of the legs or feet.51 Advise patients to seek medical advice immediately if they have reduced oral intake (such as due to acute illness or fasting) or increased fluid losses (such as due to vomiting, diarrhea, or excessive heat exposure), as it may be appropriate to temporarily discontinue dapagliflozin in those settings.1 51
-
Importance of informing patients that necrotizing infections of the perineum (Fournier gangrene) have occurred with SGLT2 inhibitor therapy.1 60 Advise patients to promptly seek medical attention if they develop pain or tenderness, redness, or swelling of the genitals or the area from the genitals back to the rectum, in addition to fever (>38°C) or malaise.1 60
-
Importance of informing patients that yeast infection may occur (e.g., vulvovaginitis, balanitis, balanoposthitis).1 38 Importance of informing female patients of the signs and symptoms of vaginal yeast infections (e.g., vaginal discharge, odor, itching) and male patients of the signs and symptoms of balanitis or balanoposthitis (e.g., rash or redness of the glans or foreskin of the penis).1 38 53 55 Advise patients of treatment options and when to seek medical advice.1 38
-
Importance of informing patients of the potential for urinary tract infections, which may be serious.1 38 Advise patients of the signs and symptoms of urinary tract infection and the need to contact a clinician promptly if such signs and symptoms occur.1 50
-
Importance of informing patients that due to the mechanism of action of dapagliflozin, patients taking the drug will test positive for glucose in their urine.1 Importance of not using urine glucose tests to monitor glycemic status while taking dapagliflozin.1
-
Risk of serious hypersensitivity reactions, such as urticaria and angioedema.1 38 If signs or symptoms of such a reaction occur, importance of discontinuing dapagliflozin and promptly informing clinician.1 38
Importance of informing patients to promptly report any signs of macroscopic hematuria or other symptoms potentially indicative of bladder cancer.1 38
-
Importance of informing patients about the importance of adherence to dietary instructions, regular physical activity, periodic blood glucose monitoring and glycosylated hemoglobin (hemoglobin A1c; HbA1c) testing, recognition and management of hypoglycemia and hyperglycemia, and assessment of diabetes complications.1 38
-
Importance of promptly seeking medical advice during periods of stress such as fever, trauma, infection, or surgery as medication requirements may change.1 38
-
Importance of taking dapagliflozin exactly as directed by clinician.1 38 (See Administration under Dosage and Administration.)
-
Importance of women informing their clinicians immediately if they are or plan to become pregnant or plan to breast-feed.1 38
-
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses (e.g., severe kidney disease).1 38 53 55
-
Importance of informing patients of other important precautionary information.1 38 (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Oral |
Tablets, film-coated |
5 mg (of dapagliflozin) |
Farxiga |
AstraZeneca |
10 mg (of dapagliflozin) |
Farxiga |
AstraZeneca |
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Oral |
Tablets, extended-release |
2.5 mg (of dapagliflozin) with Extended-release Metformin Hydrochloride 1 g |
Xigduo XR |
AstraZeneca |
2.5 mg (of dapagliflozin) with Extended-release Metformin Hydrochloride 1 g and Saxagliptin 2.5 mg |
Qternmet XR |
AstraZeneca |
||
5 mg (of dapagliflozin) with Extended-release Metformin Hydrochloride 500 mg |
Xigduo XR |
AstraZeneca |
||
5 mg (of dapagliflozin) with Extended-release Metformin Hydrochloride 1 g |
Xigduo XR |
AstraZeneca |
||
5 mg (of dapagliflozin) with Extended-release Metformin Hydrochloride 1 g and Saxagliptin 2.5 mg |
Qternmet XR |
AstraZeneca |
||
5 mg (of dapagliflozin) with Extended-release Metformin Hydrochloride 1 g and Saxagliptin 5 mg |
Qternmet XR |
AstraZeneca |
||
10 mg (of dapagliflozin) with Extended-release Metformin Hydrochloride 500 mg |
Xigduo XR |
AstraZeneca |
||
10 mg (of dapagliflozin) with Extended-release Metformin Hydrochloride 1 g |
Xigduo XR |
AstraZeneca |
||
10 mg (of dapagliflozin) with Extended-release Metformin Hydrochloride 1 g and Saxagliptin 5 mg |
Qternmet XR |
AstraZeneca |
||
Tablets, film-coated |
5 mg (of dapagliflozin) with Saxagliptin 5 mg |
Qtern |
AstraZeneca |
|
10 mg (of dapagliflozin) with Saxagliptin 5 mg |
Qtern |
AstraZeneca |
AHFS DI Essentials™. © Copyright 2024, Selected Revisions June 9, 2021. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.
References
1. AstraZeneca Pharmaceuticals. Farxiga (dapagliflozin) tablets prescribing information. Wilmington, DE; 2020 May.
2. Ferrannini E1, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010 Oct; 33:2217-24.
3. Bailey CJ, Iqbal N, T'joen C, List JF. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012 Oct; 14:951-9.
4. . Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012 May; 66:446-56.
5. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Jun 26; 375:2223-33.
6. Nauck MA, Del Prato S, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011 Sep; 34:2015-22.
7. Strojek K, Yoon KH, Hruba V. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011 Oct; 13:928-38.
8. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012 Jul; 35:1473-8.
9. Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Diabetes Care.. 2014 Mar; 37:740-50.
10. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2013 Aug; :.
11. Food and Drug Administration. Center for Drug Evaluation and Research: Application number 202293 (dapagliflozin): Medical review(s). From FDA website. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000MedR.pdf
12. Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013 Feb 20; 11
13. Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2013 Aug 1; :.
14. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012 Mar; 97:1020-31.
15. Ji L, Ma J, Li H, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014 Jan 1; 36:84-10.
16. Wilding JP, Norwood P, T'joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009 Sep; 32:1656-62.
17. DeFronzo RA, Hompesch M, Kasichayanula S et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013 Oct; 36:3169-76.
18. Yang L, Li H, Li H et al. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. Clin Ther. 2013 Aug; 35:1211-1222.
19. Obermeier M, Yao M, Khanna A et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010 Mar;; :.
20. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan; 53:17-27.
21. Kasichayanula S, Liu X, Zhang W et al. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obes Metab. 2011 Aug; 13:770-3.
22. Kasichayanula S, Liu X, Zhang W et al. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.. Clin Ther. 2011 Nov; 33:1798-808.
23. Kasichayanula S, Liu X, Pe Benito M et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013 Sep; 76:432-44.
24. Kasichayanula S, Liu X, Griffen SC, Lacreta FP, Boulton DW. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diabetes Obes Metab. 2013 Mar; 15:280-3.
25. Kasichayanula S, Liu X, Shyu WC et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011 Jan; 13:47-54.
26. Kasichayanula S, Chang M, Liu X et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012 Feb; 29:163-77.
27. Boulton DW, Kasichayanula S, Keung CF et al. Simultaneous oral therapeutic and intravenous 14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br J Clin Pharmacol. 2013 Mar; 75:763-8.
28. Merovci A, , Solis-Herrera C, Daniele G et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014 Feb 3; 124:509-14.
29. Mudaliar S, Henry RR, Boden G et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther. 2014 Mar; 16:137-44.
30. Komoroski B, Vachharajani N, Boulton D et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009 May; 85:520-6.
31. Komoroski B, Vachharajani N, Feng Y et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009 May; 85:513-9.
32. Ji L, Ma J, Li H et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014 Jan 1; 36:84-100.
33. Johnsson KM, Ptaszynska A, Schmitz B et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013 Sep-Oct; 27:473-8.
34. Kaku K, Inoue S, Matsuoka O et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2013 May; 15:432-40.
35. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014 Apr; 85:962-71.
36. Riser Taylor S, Harris KB. The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Type 2 Diabetes Mellitus. Pharmacotherapy. 2013; :. http://www.ncbi.nlm.nih.gov/pubmed/23744749?dopt=AbstractPlus
37. Johnsson KM, Ptaszynska A, Schmitz B et al, , , . Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013 Sep-Oct; 27:479-84.
38. AstraZeneca Pharmaceuticals. Farxiga (dapagliflozin) tablets medication guide. Wilmington, DE; 2018 Oct.
39. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 2015 May 15. From FDA website. Accessed 2015 July 6. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf
40. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015; 38:1638-42. http://www.ncbi.nlm.nih.gov/pubmed/26294774?dopt=AbstractPlus
41. Erondu N, Desai M, Ways K et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015; 38:1680-6. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4542268&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/26203064?dopt=AbstractPlus
42. Peters AL, Buschur EO, Buse JB et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium–glucose cotransporter 2 inhibition. Diabetes Care. 2015; 38:1687–93. http://www.ncbi.nlm.nih.gov/pubmed/26078479?dopt=AbstractPlus
43. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. 2015 Sep 10. From FDA website. Accessed 2015 Sep 13. http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm
50. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. From FDA website. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM475487.pdf
51. US Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicine canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). From FDA website. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM506772.pdf
52. Frías JP, Guja C, Hardy E et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016; 4:1004-1016. http://www.ncbi.nlm.nih.gov/pubmed/27651331?dopt=AbstractPlus
53. AstraZeneca Pharmaceuticals. Xigduo XR (dapagliflozin and extended-release metformin hydrochloride) tablets prescribing information. Wilmington, DE; 2020 Jan.
54. AstraZeneca Pharmaceuticals. Xigduo XR (dapagliflozin and extended-release metformin hydrochloride) medication guide. Wilmington, DE; 2020 Feb.
55. AstraZeneca Pharmaceuticals. Qtern (dapagliflozin and saxagliptin) tablets prescribing information. Wilmington, DE; 2020 Jan.
56. AstraZeneca Pharmaceuticals. Qtern (dapagliflozin and saxagliptin) medication guide. Wilmington, DE; 2020 Jan.
59. Bersoff-Matcha SJ, Chamberlain C, Cao C et al. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019; 170:764-9. http://www.ncbi.nlm.nih.gov/pubmed/31060053?dopt=AbstractPlus
60. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. Silver Spring, MD; 2018 Aug 29. From FDA website. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM618466.pdf
61. Cecilia-Chi W, Lim-Tio S. Fournier's syndrome: a life-threatening complication of SGLT2 inhibition in poorly controlled diabetes mellitus. 2016 Joint Annual Scientific Meeting of the Australian Diabetes Educators Association (ADEA) and Australian Diabetes Society (ADS). Abstract number 265.
62. Kumar S, Costello AJ, Colman PG. Fournier's gangrene in a man on empagliflozin for treatment of Type 2 diabetes. Diabet Med. 2017; 34:1646-1648. http://www.ncbi.nlm.nih.gov/pubmed/28887847?dopt=AbstractPlus
70. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380:347-357. http://www.ncbi.nlm.nih.gov/pubmed/30415602?dopt=AbstractPlus
71. Fioretto P, Del Prato S, Buse JB et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes Obes Metab. 2018; 20:2532-2540. http://www.ncbi.nlm.nih.gov/pubmed/29888547?dopt=AbstractPlus
84. Trujillo JM, Nuffer WA. Impact of sodium-glucose cotransporter 2 inhibitors on nonglycemic outcomes in patients with type 2 diabetes. Pharmacotherapy. 2017; 37:481-491. http://www.ncbi.nlm.nih.gov/pubmed/28102030?dopt=AbstractPlus
85. Inzucchi SE, Zinman B, Wanner C et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015; 12:90-100. http://www.ncbi.nlm.nih.gov/pubmed/25589482?dopt=AbstractPlus
86. Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380:2295-2306. http://www.ncbi.nlm.nih.gov/pubmed/30990260?dopt=AbstractPlus
87. Jardine MJ, Mahaffey KW, Neal B et al. The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol. 2017; 46:462-472. http://www.ncbi.nlm.nih.gov/pubmed/29253846?dopt=AbstractPlus
88. Ingelfinger JR, Rosen CJ. Clinical credence - SGLT2 inhibitors, diabetes, and chronic kidney disease. N Engl J Med. 2019; 380:2371-2373. http://www.ncbi.nlm.nih.gov/pubmed/30990261?dopt=AbstractPlus
90. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. http://www.ncbi.nlm.nih.gov/pubmed/31535829?dopt=AbstractPlus
100. Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380:2295-2306. http://www.ncbi.nlm.nih.gov/pubmed/30990260?dopt=AbstractPlus
101. AstraZeneca Pharmaceuticals. Qternmet XR (dapagliflozin, saxagliptin, and metformin hydrochloride) extended-release tablets prescribing information. Wilmington, DE; 2020 Jan.
698. Garber AJ, Handelsman Y, Grunberger G et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm 2020 executive summary. Endocr Pract. 2020; 26:107-139. http://www.ncbi.nlm.nih.gov/pubmed/32022600?dopt=AbstractPlus
699. Zelniker TA, Wiviott SD, Raz I et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019; 139:2022-2031. http://www.ncbi.nlm.nih.gov/pubmed/30786725?dopt=AbstractPlus
704. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020; 43:S98-S110. http://www.ncbi.nlm.nih.gov/pubmed/31862752?dopt=AbstractPlus
705. American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020; 43:S111-S134. http://www.ncbi.nlm.nih.gov/pubmed/31862753?dopt=AbstractPlus
706. American Diabetes Association. 11. Microvascular complications and foot care: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020; 43:S135-S151. http://www.ncbi.nlm.nih.gov/pubmed/31862754?dopt=AbstractPlus
Frequently asked questions
More about dapagliflozin
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (180)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: SGLT-2 inhibitors
- Breastfeeding
- En español